Centessa Pharmaceuticals plc American Depositary Shares
CNTAStock
$40.50+69.17%52W
Market Cap$6.27B
P/E—
Div yield—
Beta0.36
Price Chart
Favorite Metrics
Price vs S&P 500 (26W)47.11%
Price vs S&P 500 (4W)4.08%
VGM Score82.37
Market Capitalization$6.27B
Earnings Surprise History
Q1 26-0.52est. -0.40
Analyst Recommendations
Apr 2026
May 2026
Jun 2026
Jul 2026
4.05
3.68
3.68
3.68
Industry Peers — Pharmaceuticals(563)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
CNTACentessa Pharmaceuticals plc American Depositary Shares | — | — | A | $40.50 |
| LLYEli Lilly & Co. | D | B | B | $1169.17 |
| JNJJohnson & Johnson | D | C | B | $249.97 |
| ABBVABBVIE INC. | D | C | B | $254.39 |
| MRKMerck & Co., Inc. | C | C | B | $127.63 |
| NVSNovartis AG | C | C | C | $152.73 |
| NVONovo-Nordisk A/S | C | B | C | $51.48 |
| AZNAstraZeneca PLC | C | B | C | $169.29 |
| ABTAbbott Laboratories | C | C | D | $98.83 |
| PFEPfizer Inc. | B | C | C | $25.14 |
| VRTXVertex Pharmaceuticals Inc | D | C | C | $486.03 |
About
Centessa Pharmaceuticals is a clinical-stage biopharmaceutical company with a portfolio of therapeutic candidates across multiple disease areas. Key programs include SerpinPC for hemophilia, LB101 for solid tumors, ORX750 for narcolepsy and sleep disorders, and MGX292 for pulmonary arterial hypertension, plus an undisclosed solid tumor program.